Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pantoprazole + amoxicillin is a combination of two pharmaceutical agents used together primarily in the management of gastrointestinal conditions associated with *Helicobacter pylori* infection, such as peptic ulcer disease and gastritis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells. Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis, leading to bacterial cell death. When used together (often with an additional antibiotic such as clarithromycin), this combination helps eradicate *H. pylori* by reducing stomach acidity (improving antibiotic efficacy) and directly killing bacteria[6][7]. The combination may be prescribed as part of dual or triple therapy regimens for *H. pylori*-associated ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pantoprazole + amoxicillin.